Key result
Cisplatin-based chemotherapy for advanced testicular cancer was associated with predominantly asymptomatic high tone hearing loss (77%) and peripheral nerve damage (50%) at 75 months median follow-up.
Why the study?
Does cisplatin-based combination chemotherapy cause late toxicity in men with advanced testicular cancer?
Cohort (n=30)
Does cisplatin-based combination chemotherapy cause late toxicity in men with advanced testicular cancer?
Cisplatin-based chemotherapy for advanced testicular cancer is associated with asymptomatic hearing and nerve abnormalities and elevated cholesterol, but is relatively free of major long-term side effects.
No takes yet. Share an insight, caveat, or question.
Supports surveillance for subclinical ototoxicity and neuropathy in survivors; leaves open optimal prevention strategies.
Boyer et al. (1990) conducted a cohort in metastatic testicular cancer (n=30). cisplatin-based combination chemotherapy vs. control population was evaluated on Type and frequency of chronic toxicity. Cisplatin-based chemotherapy for advanced testicular cancer was associated with predominantly asymptomatic high tone hearing loss (77%) and peripheral nerve damage (50%) at 75 months median follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: